Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019357 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00019357: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00019357 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019357, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining white blood cells, which have been activated by a vaccine, with interleukin-2 may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 plus activated white blood cells in treating patients with cancer that has not responded to chemotherapy or radiation therapy.
Interventions
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL aldesleukin
- BIOLOGICAL therapeutic tumor infiltrating lymphocytes
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-06 |
| Phase | Phase 1 |
What the finished NCT00019357 record still lists
NCT00019357 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which therapeutic autologous lymphocytes is the first listed.
NCT00019357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019357 about?
NCT00019357 is a clinical study titled "Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining white blood cells, which have been activated by a vaccine, with interleukin-2 may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 plus activated white blood ...
What is the current status of trial NCT00019357?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-06.
What interventions are being tested in trial NCT00019357?
The interventions under investigation include: therapeutic autologous lymphocytes (BIOLOGICAL), aldesleukin (BIOLOGICAL), therapeutic tumor infiltrating lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00019357?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia